Horizon Stock Today


USD 61.89  0.80  1.28%   

Market Performance
0 of 100
Odds Of Distress
Less than 18
Horizon Therapeutics is selling at 61.89 as of the 1st of October 2022; that is -1.28 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 61.85. Horizon Therapeutics has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Horizon Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2022 and ending today, the 1st of October 2022. Click here to learn more.
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois Chicago, Illinois Lake Forest, Illinois South San Francisco, California Washington, D.C. The company has 226.82 M outstanding shares of which 7.42 M shares are currently shorted by private and institutional investors with about 3.62 trading days to cover. More on Horizon Therapeutics

Moving together with Horizon Therapeutics

+0.88JNJJohnson Johnson TrendingPairCorr
+0.84PFEPfizer Inc TrendingPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Horizon Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Horizon Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Horizon Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Horizon Therapeutics generated a negative expected return over the last 90 days
Horizon Therapeutics has high historical volatility and very poor performance
Over 95.0% of the company shares are owned by institutional investors
Latest headline from www.marketscreener.com: Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner - Marketscreener.com
Chairman, CEO and PresTimothy Walbert
Thematic Ideas
(view all).
Average Analyst Recommendation
Analysts covering Horizon Therapeutics report their recommendations after researching Horizon Therapeutics' financial statements, talking to executives and customers, or listening in on Horizon Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Horizon Therapeutics. The Horizon consensus assessment is calculated by taking the average forecast from all of the analysts covering Horizon Therapeutics.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Horizon Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Horizon Therapeutics (HZNP) is traded on NASDAQ Exchange in USA and employs 1,940 people. The company currently falls under 'Large-Cap' category with current market capitalization of 14.02 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Horizon Therapeutics's market, we take the total number of its shares issued and multiply it by Horizon Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Horizon Therapeutics conducts business under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 226.82 M outstanding shares of which 7.42 M shares are currently shorted by private and institutional investors with about 3.62 trading days to cover. Horizon Therapeutics currently holds about 1.64 B in cash with 1.25 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.15.
Check Horizon Therapeutics Probability Of Bankruptcy
Horizon Therapeutics secures a total of 226.82 Million outstanding shares. The majority of Horizon Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Horizon Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Horizon Therapeutics. Please pay attention to any change in the institutional holdings of Horizon Therapeutics as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Horizon Ownership Details

Horizon Stock Price Odds Analysis

Contingent on a normal probability distribution, the odds of Horizon Therapeutics jumping above the current price in 90 days from now is about 80.79%. The Horizon Therapeutics probability density function shows the probability of Horizon Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Horizon Therapeutics has a beta of 0.722. This usually indicates as returns on the market go up, Horizon Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Horizon Therapeutics will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Horizon Therapeutics is significantly underperforming DOW.
  Odds Below 61.89HorizonTargetOdds Above 61.89
19.13%90 days
Based on a normal probability distribution, the odds of Horizon Therapeutics to move above the current price in 90 days from now is about 80.79 (This Horizon Therapeutics probability density function shows the probability of Horizon Stock to fall within a particular range of prices over 90 days) .

Horizon Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Horizon Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Horizon Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Horizon Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares20.9 M1.7 B
Blackrock IncCommon Shares14.6 M1.2 B
View Horizon Therapeutics Diagnostics

Horizon Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Horizon Therapeutics market risk premium is the additional return an investor will receive from holding Horizon Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Horizon Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Horizon Therapeutics' alpha and beta are two of the key measurements used to evaluate Horizon Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Horizon Stock Against Markets

Picking the right benchmark for Horizon Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Horizon Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Horizon Therapeutics is critical whether you are bullish or bearish towards Horizon Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Horizon Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Balance Of Power Now


Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
All  Next Launch Module

Horizon Therapeutics Corporate Directors

Horizon Therapeutics corporate directors refer to members of a Horizon Therapeutics board of directors. The board of directors generally takes responsibility for the Horizon Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Horizon Therapeutics' board members must vote for the resolution. The Horizon Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Ronald Pauli - Independent DirectorProfile
Pascale Witz - DirectorProfile
Thomas Watkins - Independent DirectorProfile
Jeffrey Himawan - Independent DirectorProfile

Invested in Horizon Therapeutics?

The danger of trading Horizon Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Horizon Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Horizon Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Horizon Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please check Risk vs Return Analysis. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for analysis

When running Horizon Therapeutics price analysis, check to measure Horizon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Horizon Therapeutics is operating at the current time. Most of Horizon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Horizon Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Horizon Therapeutics' price. Additionally, you may evaluate how the addition of Horizon Therapeutics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Horizon Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Horizon Therapeutics. If investors know Horizon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Horizon Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Horizon Therapeutics is measured differently than its book value, which is the value of Horizon that is recorded on the company's balance sheet. Investors also form their own opinion of Horizon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Horizon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Horizon Therapeutics' market value can be influenced by many factors that don't directly affect Horizon Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Horizon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Horizon Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Horizon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.